WUXI APPTEC Annual Revenue as on December-2019 ending is 12872 Million CNY
Annual Net Income
WUXI APPTEC Annual Net Income as on December-2019 ending is 1854 Million CNY
About Company Business:
WUXI APPTEC is a pharmaceutical and biotechnology company with headquarters in China.
As on 2020, WuXi AppTec has 29 sites worldwide and more than 25,000 employees globally. WuXi today provides a broad portfolio of R&D and manufacturing services that support over 4,100 collaborative partners worldwide.
AIER Eye Hospital Group is China's leading ophthalmology hospital group that covers Asia, Europe, and North America with huge scale and outstanding medical capacity. It has three listed companies in China (stock code: 300015) , Europe (Spain: CBAV), and Southeast Asia (Singapore: 40T) with a total number of more than 600 specialized eye hospitals and centers and the annual outpatient visits in mainland China exceeded 10 million.
WuXi Biologics, a Hong Kong-listed company, is a leading global biologics services provider that offers comprehensive, integrated and highly customizable services. The company offers multinational pharmaceutical and biotechnological companies in the world end-to-end solutions empowering anyone and any company to discover, develop and manufacture biologics from concept to commercial manufacturing. Our services are designed to help our worldwide clients shorten the discovery and development time and lower the cost of biologics.